Jeronselvain Signs Joint Research and Development Agreement with COSMAX NBT

Pharmaceutical and bio company Jeron Selvain announced on the 17th that it has signed a joint research memorandum of understanding (MOU) with health functional food (HFF) research, development, and manufacturing (ODM) company Cosmax NBT for the development of individually recognized raw materials. Through this agreement, both companies will collaborate on the overall development of HFF, including material functionality, formulation research, and finished product manufacturing, as well as other cooperative tasks.

Specifically, the two companies will cooperate in ▲ research and development for the registration of individually recognized functional raw materials ▲ production and distribution of finished products applying functional raw materials ▲ securing government research and development (R&D) projects for functional research and development. In addition, they plan to promote multifaceted business cooperation for mutual growth.

Through this agreement, the companies aim to discover materials focused on oral health and bone health and obtain certification for individually recognized raw materials. Jeron Selvain will provide its accumulated research capabilities from pharmaceutical development, while Cosmax NBT, which has a global production chain, will be responsible for manufacturing finished products applying functional raw materials.

Cosmax NS, a specialized research company and subsidiary of Cosmax NBT, will support research and development. Through this, they plan to realize the transformation of pharmaceuticals into health functional foods and further extend this to cosmetics as health functional foods.

Jeron Selvain is a pharmaceutical and bio company, with representative products including the prescription drug for pain and inflammation treatment, ‘Selvain Injection’. It researches and develops products for the treatment and recovery of diseases related to aging progression. Its strengths lie particularly in the treatment of inflammatory diseases and the regeneration of degenerated tissues. The company is accelerating research and development to expand indications for treatments such as periodontitis and pulmonary diseases.

Cosmax NBT is a Cosmax Group affiliate equipped with both production and material development capabilities. To date, it has developed a total of eight individually recognized raw materials (based on functionality), including the vaginal health probiotic ‘Respecta’ and the patchouli extract ‘Agatri’. It also operates global production bases in Korea, the United States, Australia, and other locations.

Kim Deok-gyu, CEO of Jeron Selvain, said, “We have high expectations for jointly developing with Cosmax NBT, a strong player in the HFF field,” adding, “The research capabilities accumulated by Jeron Selvain will be utilized in various ways through this agreement.”

This content was produced with the assistance of AI translation services.